Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dabrafenib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06653517
What this trial is testing

Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma

Who this might be right for
AmeloblastomaBRAF V600E Mutation Positive
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University 12
Testing effectiveness (Phase 2)Looking for participantsNCT05525273
What this trial is testing

Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma

Who this might be right for
Craniopharyngioma
Eva Marie Erfurth, MD, PhD 25
Testing effectiveness (Phase 2)WithdrawnNCT02143050
What this trial is testing

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

Who this might be right for
Melanoma
University of Louisville
Testing effectiveness (Phase 2)Active Not RecruitingNCT04675710
What this trial is testing

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Who this might be right for
Thyroid Gland Anaplastic CarcinomaThyroid Gland Squamous Cell Carcinoma
M.D. Anderson Cancer Center 30
Early research (Phase 1)Study completedNCT03026517
What this trial is testing

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 18
Testing effectiveness (Phase 2)Ended earlyNCT01721603
What this trial is testing

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

Who this might be right for
BRAFV600E Melanoma Patients
University of California, San Francisco 2
Testing effectiveness (Phase 2)Ended earlyNCT01978236
What this trial is testing

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Who this might be right for
Melanoma and Brain Metastases
GlaxoSmithKline 6
Early research (Phase 1)Study completedNCT02027961
What this trial is testing

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Who this might be right for
Melanoma
MedImmune LLC 68
Testing effectiveness (Phase 2)Study completedNCT02083354
What this trial is testing

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Who this might be right for
CancerMelanoma
Novartis Pharmaceuticals 77
Testing effectiveness (Phase 2)Active Not RecruitingNCT04238624
What this trial is testing

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerThyroid CancerBRAF Gene Mutation+1 more
Memorial Sloan Kettering Cancer Center 16
Large-scale testing (Phase 3)Ended earlyNCT02967692
What this trial is testing

The Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 568
Early research (Phase 1)Study completedNCT01340833
What this trial is testing

Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Who this might be right for
Cancer
GlaxoSmithKline 6
Early research (Phase 1)Study completedNCT01767454
What this trial is testing

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Who this might be right for
Solid Tumours
GlaxoSmithKline 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT04201457
What this trial is testing

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Who this might be right for
Low Grade Glioma (LGG) of Brain With BRAF AberrationHigh Grade Glioma (HGG) of the Brain With BRAF AberrationLow Grade Glioma of Brain With Neurofibromatosis Type 1
Pediatric Brain Tumor Consortium 57
Not applicableNo Longer AvailableNCT04507919
What this trial is testing

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Carcinoma
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)WithdrawnNCT03794297
What this trial is testing

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

Who this might be right for
Erdheim-Chester Disease
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT02872259
What this trial is testing

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Who this might be right for
Melanoma
Haukeland University Hospital 74
Early research (Phase 1)Study completedNCT02110355
What this trial is testing

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Who this might be right for
Advanced MalignancyAdvanced Solid TumorsCancer+4 more
Kartos Therapeutics, Inc. 31
Testing effectiveness (Phase 2)Study completedNCT01619774
What this trial is testing

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

Who this might be right for
Melanoma
M.D. Anderson Cancer Center 28
Testing effectiveness (Phase 2)Study completedNCT03244956
What this trial is testing

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

Who this might be right for
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
Gustave Roussy, Cancer Campus, Grand Paris 40
Next Page